ClinicalTrials.gg
CompletedNCT01412424Updated Aug 17, 2017Results posted

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

A Phase 3 interventional study of Octreotide capsules in Acromegaly, sponsored by Chiasma, Inc.. Completed at 36 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-17.

Sponsored by Chiasma, Inc. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
155
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
2nd of 25
155 · median 56
Started
2012
with 1 other
Phase 3
12 of 25
1 open now
Registered
15th of 25
by date
Lead sponsor
3 of 25
Chiasma, Inc.

Among the 25 studies testing octreotide in Acromegaly, this one is the 2nd largest by enrollment, is one of 2 that started in 2012, is one of 12 in phase 3, and was the 15th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety of MYCAPSSA™ treatment in patients with acromegaly.

Read the detailed description

The study consisted of 2 periods, a Core Treatment Period of up to 7 months and an optional Extension Treatment Period of up to 6 months, for a total study duration of up to 13 months. The Core Treatment Period consisted of 2 phases, a Dose Escalation Phase of at least 2 months to identify the therapeutic dose for each study participant and a Fixed Dose Phase of 2 to 5 months during which the therapeutic dose was maintained.

Participants were eligible to enter the Fixed Dose Phase of the Core Treatment Period if they were clinically and biochemically controlled. The same criteria were used to allow entry into the voluntary 6-month Extension Treatment Period.

The Core Treatment Period of the study was completed if the participant had at least 2 months of treatment in the Fixed Dose Phase and a total treatment duration of at least 7 months. Participants who elected to continue into the Extension Treatment Period maintained their therapeutic dose during this period. At the end of the study (after the last dose of MYCAPSSA in either the Core Treatment Period or the Extension Treatment Period), there was a 2-week follow-up period for safety assessments.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • acromegaly
  • IGF-1
  • growth hormone
  • Octreolin
  • octreotide
  • somatostatin analog
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects, aged 18 to 75 years old, inclusive.
  • Subjects with acromegaly defined as documented evidence of growth hormone-secreting pituitary tumor that is abnormally responsive to glucose, or documented elevated insulin-like growth factor-1 (IGF-1), who are currently receiving a stable dose of a somatostatin analog for at least the previous 3 months.
  • A serum IGF-1 level \< 1.3 x the (ULN) and a serum growth hormone (GH) level \< 2.5 ng/mL.
  • Subjects able and willing to comply with the requirements of the protocol.
  • Subjects able to swallow capsules.
  • Subjects able to understand and sign written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Receiving regular injections of a somatostatin analog less frequently than once a month, ie, longer than every 4 weeks.
  • Symptomatic cholelithiasis.
  • Received pituitary radiotherapy within ten years prior to screening.
  • Undergone pituitary surgery within the prior 6 months.
  • Any condition that may jeopardize study participation.
  • gastrointestinal (GI), renal, or hepatic disease as determined by the Investigator.
  • Conditions (eg, bariatric surgery) significantly affecting gastric acidity or emptying.
  • Current use (within 1 month) of proton pump inhibitors (PPIs) and current chronic use of H2-antagonists.
  • Female patients who are pregnant or lactating.
  • Current or recent (\< 3 months) therapy with pegvisomant.
  • Current or recent (\< 2 months) therapy with cabergoline.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Octreotide capsules

    Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.

    Drug: Octreotide capsules

Interventions

  • Octreotide was provided in hard gelatin capsules.

    Also known as: MYCAPSSA™, Formerly known as Octreolin™

06

What researchers measure

Primary outcomes

  1. Percentage of Responders at the End of the Core Treatment Period

    A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

    Time frame: End of the core treatment period (up to 7 months)

  2. Percentage of Responders at the End of the Extension Treatment Period

    A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

    Time frame: End of the extension treatment period (up to 13 months)

Secondary outcomes

  1. Percentage of Participants With Specified IGF-1 and GH Concentrations at Baseline and at the End of the Core Treatment Period

    Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at Baseline and at the end of the core treatment period (ECTP): IGF-1 \< 1.3 times the upper limit of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

    Time frame: Baseline and the end of the core treatment period (up to 7 months)

  2. Maintenance of Response During the Fixed Dose Phase of the Core Treatment Period

    Maintenance of response during the fixed dose phase of the core treatment period was defined as the percentage of participants with an insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal at the beginning of the fixed dose phase of the core treatment period and at the end of the core treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.

    Time frame: Beginning of the fixed dose phase of the core treatment period and the end of the core treatment period (up to 7 months)

  3. Percentage of Participants With Specified IGF-1 and GH Concentrations at the Beginning and at the End of the Extension Treatment Period

    Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at the beginning (BETP) and at the end (EETP) of the extension treatment period: IGF-1 \< 1.3 times the upper level of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

    Time frame: Beginning and the end of the extension treatment period (up to 6 months)

  4. Maintenance of Response During the Extension Treatment Period

    Maintenance of an insulin-like growth factor-1 (IGF-1) response during the extension treatment period was defined as the percentage of participants with an IGF-1 concentration \< 1.3 times the upper limit of normal at the beginning of the extension treatment period and at the end of the extension treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.

    Time frame: Beginning of the extension treatment period and the end of the extension treatment period (up to 13 months)

  5. Percentage of Participants With Improved or Maintained Acromegaly Symptoms at the End of the Extension Treatment Period

    The severity (absent, mild, moderate, severe) of the 5 acromegaly symptoms headache, perspiration, asthenia, swelling of extremities, and joint pain was assessed at Baseline and at the end of the extension treatment period. The percentage of participants with improved or maintained (no change) acromegaly symptoms from Baseline at the end of the extension treatment period is reported.

    Time frame: Baseline and the end of the extension treatment period (up to 13 months)

  6. Percentage of Participants With ≥ 1, 2, or 3 Acromegaly Symptoms at Baseline and at the End of the Extension Treatment Period

    Reported is the percentage of participants who had ≥ 1, 2, or 3 of the 5 symptoms of acromegaly (headaches, perspiration, asthenia, swelling of extremities, or joint pain) of any severity (mild, moderate, or severe). This was a post hoc analysis.

    Time frame: Baseline and the end of the extension treatment period (up to 13 months)

07

Results

Posted Dec 1, 2015

Participant flow

Core Treatment Period
Participant flow — Core Treatment Period
MilestoneOctreotide Capsules
Started155
Completed102
Not completed53
Withdrew: Treatment failure24
Withdrew: Adverse event21
Withdrew: Patient request5
Withdrew: Lost to follow-up2
Withdrew: Sponsor request1
Extension Treatment Period
Participant flow — Extension Treatment Period
MilestoneOctreotide Capsules
Started88
Completed82
Not completed6
Withdrew: Adverse event2
Withdrew: Treatment failure2
Withdrew: Patient request2

Outcome measures

PrimaryPercentage of Responders at the End of the Core Treatment Period

A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

Time frame:
End of the core treatment period (up to 7 months)
Reported as:
Number · Percentage of responders
Percentage of Responders at the End of the Core Treatment Period
Percentage of respondersOctreotide 40 mgOctreotide 60 mgOctreotide 80 mgOctreotide 40, 60, or 80 mg - All Participants
Percentage of Responders at the End of the Core Treatment Period86.9 (83.0 to 98.1)66.7 (48.2 to 82.0)40.4 (27.6 to 54.2)64.9 (58.4 to 74.2)
PrimaryPercentage of Responders at the End of the Extension Treatment Period

A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

Time frame:
End of the extension treatment period (up to 13 months)
Reported as:
Number · Percentage of responders
Percentage of Responders at the End of the Extension Treatment Period
Percentage of respondersOctreotide Capsules
Percentage of Responders at the End of the Extension Treatment Period78.4 (68.4 to 86.5)
SecondaryPercentage of Participants With Specified IGF-1 and GH Concentrations at Baseline and at the End of the Core Treatment Period

Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at Baseline and at the end of the core treatment period (ECTP): IGF-1 \< 1.3 times the upper limit of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

Time frame:
Baseline and the end of the core treatment period (up to 7 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Specified IGF-1 and GH Concentrations at Baseline and at the End of the Core Treatment Period
Percentage of participantsOctreotide Capsules
IGF-1 < 1.3 & GH < 5.0: Baseline91.4
IGF-1 < 1.3 & GH < 5.0: ECTP65.6
IGF-1 < 1.3 & GH < 1.0: Baseline62.9
IGF-1 < 1.3 & GH < 1.0: ECTP53.0
IGF-1 ≤ 1.0 & GH < 5.0: Baseline63.6
IGF-1 ≤ 1.0 & GH < 5.0: ECTP35.8
IGF-1 ≤ 1.0 & GH < 2.5: Baseline61.6
IGF-1 ≤ 1.0 & GH < 2.5: ECTP35.8
IGF-1 ≤ 1.0 & GH < 1.0: Baseline43.0
IGF-1 ≤ 1.0 & GH < 1.0: ECTP31.8
IGF-1 < 1.3: Baseline91.4
IGF-1 < 1.3: ECTP66.9
IGF-1 ≤ 1.0: Baseline63.6
IGF-1 ≤ 1.0: ECTP37.1
GH < 5.0: Baseline100.0
GH < 5.0: ECTP97.4
GH < 2.5: Baseline96.0
GH < 2.5: ECTP94.7
GH < 1.0: Baseline66.2
GH < 1.0: ECTP77.5
IGF-1 ≥ 1.3 & GH < 2.5: Baseline7.3
IGF-1 ≥ 1.3 & GH < 2.5: ECTP29.8
IGF-1 < 1.3 & GH ≥ 2.5: Baseline2.6
IGF-1 < 1.3 & GH ≥ 2.5: ECTP0.7
IGF-1 ≥ 1.3 & GH ≥ 2.5: Baseline1.3
IGF-1 ≥ 1.3 & GH ≥ 2.5: ECTP2.0
SecondaryMaintenance of Response During the Fixed Dose Phase of the Core Treatment Period

Maintenance of response during the fixed dose phase of the core treatment period was defined as the percentage of participants with an insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal at the beginning of the fixed dose phase of the core treatment period and at the end of the core treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.

Time frame:
Beginning of the fixed dose phase of the core treatment period and the end of the core treatment period (up to 7 months)
Reported as:
Number · Percentage of participants
Maintenance of Response During the Fixed Dose Phase of the Core Treatment Period
Percentage of participantsOctreotide Capsules
Beginning of the FDP of the CTP82.7
End of the CTP80.0
SecondaryPercentage of Participants With Specified IGF-1 and GH Concentrations at the Beginning and at the End of the Extension Treatment Period

Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at the beginning (BETP) and at the end (EETP) of the extension treatment period: IGF-1 \< 1.3 times the upper level of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.

Time frame:
Beginning and the end of the extension treatment period (up to 6 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Specified IGF-1 and GH Concentrations at the Beginning and at the End of the Extension Treatment Period
Percentage of participantsOctreotide Capsules
IGF-1 < 1.3 & GH < 5.0: BETP84.1
IGF-1 < 1.3 & GH < 5.0: EETP79.5
IGF-1 < 1.3 & GH < 1.0: BETP69.3
IGF-1 < 1.3 & GH < 1.0: EETP68.2
IGF-1 ≤ 1.0 & GH < 5.0: BETP48.9
IGF-1 ≤ 1.0 & GH < 5.0: EETP50.0
IGF-1 ≤ 1.0 & GH < 2.5: BETP48.9
IGF-1 ≤ 1.0 & GH < 2.5: EETP50.0
IGF-1 ≤ 1.0 & GH < 1.0: BETP42.0
IGF-1 ≤ 1.0 & GH < 1.0: EETP44.3
IGF-1 < 1.3: BETP84.1
IGF-1 < 1.3: EETP79.5
IGF-1 ≤ 1.0: BETP48.9
IGF-1 ≤ 1.0: EETP50.0
GH < 5.0: BETP100.0
GH < 5.0: EETP97.7
GH < 2.5: BETP98.9
GH < 2.5: EETP95.5
GH < 1.0: BETP83.0
GH < 1.0: EETP83.0
IGF-1 ≥ 1.3 & GH < 2.5: BETP14.8
IGF-1 ≥ 1.3 & GH < 2.5: EETP17.0
IGF-1 < 1.3 & GH ≥ 2.5: BETP0.0
IGF-1 < 1.3 & GH ≥ 2.5: EETP1.1
IGF-1 ≥ 1.3 & GH ≥ 2.5: BETP1.1
IGF-1 ≥ 1.3 & GH ≥ 2.5: EETP3.4
SecondaryMaintenance of Response During the Extension Treatment Period

Maintenance of an insulin-like growth factor-1 (IGF-1) response during the extension treatment period was defined as the percentage of participants with an IGF-1 concentration \< 1.3 times the upper limit of normal at the beginning of the extension treatment period and at the end of the extension treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.

Time frame:
Beginning of the extension treatment period and the end of the extension treatment period (up to 13 months)
Reported as:
Number · Percentage of participants
Maintenance of Response During the Extension Treatment Period
Percentage of participantsOctreotide Capsules
Maintenance of Response During the Extension Treatment Period87.8 (78.2 to 94.3)
SecondaryPercentage of Participants With Improved or Maintained Acromegaly Symptoms at the End of the Extension Treatment Period

The severity (absent, mild, moderate, severe) of the 5 acromegaly symptoms headache, perspiration, asthenia, swelling of extremities, and joint pain was assessed at Baseline and at the end of the extension treatment period. The percentage of participants with improved or maintained (no change) acromegaly symptoms from Baseline at the end of the extension treatment period is reported.

Time frame:
Baseline and the end of the extension treatment period (up to 13 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Improved or Maintained Acromegaly Symptoms at the End of the Extension Treatment Period
Percentage of participantsOctreotide Capsules
Maintained27 (18.3 to 37.8)
Improved57 (45.8 to 67.3)
SecondaryPercentage of Participants With ≥ 1, 2, or 3 Acromegaly Symptoms at Baseline and at the End of the Extension Treatment Period

Reported is the percentage of participants who had ≥ 1, 2, or 3 of the 5 symptoms of acromegaly (headaches, perspiration, asthenia, swelling of extremities, or joint pain) of any severity (mild, moderate, or severe). This was a post hoc analysis.

Time frame:
Baseline and the end of the extension treatment period (up to 13 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥ 1, 2, or 3 Acromegaly Symptoms at Baseline and at the End of the Extension Treatment Period
Percentage of participantsOctreotide Capsules
1 Symptom - Baseline78
1 Symptom - End of the extension treatment period65
2 Symptoms - Baseline61
2 Symptoms - End of the extension treatment period43
3 Symptoms - Baseline43
3 Symptoms - End of the extension treatment period25

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Octreotide 40 mg1/155 (0.6%)9/155 (5.8%)103/155 (66.5%)
Octreotide 60 mg0/91 (0%)7/91 (7.7%)51/91 (56%)
Octreotide 80 mg1/58 (1.7%)8/58 (13.8%)31/58 (53.4%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventOctreotide 40 mgOctreotide 60 mgOctreotide 80 mg
CholelithiasisHepatobiliary disorders0/1551/911/58
Cholecystitis acuteHepatobiliary disorders0/1550/911/58
HeadacheNervous system disorders0/1550/911/58
Herpes simplex ophthalmicInfections and infestations0/1550/911/58
Urinary tract infectionInfections and infestations0/1550/911/58
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1550/911/58
Acute myocardial infarctionCardiac disorders0/1550/911/58
Intervertebral disc protusionMusculoskeletal and connective tissue disorders0/1550/911/58
TinnitusEar and labyrinth disorders0/1550/911/58
VertigoEar and labyrinth disorders0/1550/911/58
Most frequent other events
Showing 10 of 22
Most frequent other events
EventOctreotide 40 mgOctreotide 60 mgOctreotide 80 mg
HeadacheNervous system disorders44/15518/9120/58
ArthralgiaMusculoskeletal and connective tissue disorders25/15520/9111/58
NauseaGastrointestinal disorders30/15514/916/58
AstheniaGeneral disorders27/15511/918/58
HyperhidrosisSkin and subcutaneous tissue disorders23/1559/916/58
Oedema peripheralGeneral disorders19/1558/915/58
DiarrhoeaGastrointestinal disorders18/15511/914/58
NasopharyngitisInfections and infestations5/1554/915/58
Abdominal painGastrointestinal disorders5/1557/911/58
DyspepsiaGastrointestinal disorders11/1552/911/58

Baseline characteristics

Safety population: All participants enrolled in the study who received any amount of the study drug.

Age, Continuous
Age, Continuous(Years)Octreotide Capsules
Mean54.2 ± 11.54
Sex: Female, Male
Sex: Female, Male(Participants)Octreotide Capsules
Female88
Male67
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Octreotide Capsules
Hispanic or Latino20
Not Hispanic or Latino135
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Octreotide Capsules
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White137
More than one race0
Unknown or Not Reported16
08

Study locations

36 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Campus Charité Mitte
    Berlin, Germany
  • ENDOC Center for Endocrine Tumors
    Hamburg, 20357, Germany
  • Medizinische Klinik Innenstadt
    Munich, 80336, Germany
  • Max Planck Institute of Psychiatry
    Munich, 80804, Germany
  • Praxis for Endocrimology and Diabetology in Oldenburg
    Oldenburg, 26122, Germany
  • Military Hospital, State Health Center 2nd Department of Internal Medicine
    Budapest, 1062, Hungary
  • Semmelweiss University
    Budapest, 1088, Hungary
  • University of Pecs
    Pecs, 7624, Hungary
  • University of Szeged
    Szeged, 6720, Hungary
  • Servizio di Endocrinologia A.O. Spedali Civili di Brescia
    Brescia, 25128, Italy
  • Dipartimento Clinico Sperimentale di Medicina e Farmacologia
    Messina, 98125, Italy
  • Ospedale Molinette
    Torino, 10126, Italy
  • Hospital of Lithuanian University of Health Sciences Kauno Klinikos
    Kaunas, 50009, Lithuania
  • Vilnius University Hospital Santariskiu Clinics Center of Endocrinology
    Vilnius, 8661, Lithuania
  • Unidad de Investigacion Clinica Cardiometabolica de Occidente
    Guadalajara Jalisco, 44150, Mexico
  • Instituto Nacional de Neurologia y Neurocirugía - National Institute of Neurology and Neurosurgery
    Mexico City, 14269, Mexico
  • Centro Medico ABC
    Mexico D.F., 5300, Mexico
  • Leiden University Medical Centre
    Leiden, 2333 ZA, Netherlands
  • Erasmus University Medical Center
    Rotterdam, 3015 CE, Netherlands
  • Autonomous Public Clinical Hospital No. 5
    Katowice, 40- 952, Poland
  • Department of Endocrinology - Jagiellonian University, Krakow
    Krakow, 31-501, Poland
  • Clinical Hospital of Medical University in Poznan
    Poznan, 60-355, Poland
  • Bielanski Hospital
    Warsaw, 01 - 809, Poland
  • Wroclaw Medical University
    Wroclaw, 50-367, Poland
  • Endocrinology Institute C.I.Parhon
    Bucharest, 11863, Romania
  • County Emergency Hospital, Sf. Spiridon, Department of Endocrinology
    Iasi, 700111, Romania
  • Clinic for Endocrinology, Diabetes and Metabolism Diseases, Clinical Center of Serbia
    Belgrade, 11000, Serbia
  • Clinical Center of Vojvodina
    Novi Sad, 21000, Serbia
  • University Hospital Bratislava, Hospital of L.Derer
    Bratislava, 833 05, Slovakia
  • National Institute of Endocrinology and Diabetology
    Ľubochňa, 034 91, Slovakia
  • Department of Endocrinology and Diabetes, University Medical Centre
    Ljubliana, 1525, Slovenia
  • University of Warwick - Medical School
    Coventry, CV2 2DX, United Kingdom
  • St Bartholomew's Hospital West
    London, EC1M 6BQ, United Kingdom
  • The Christie Hospital NHS Trust
    Manchester, M13 9WL, United Kingdom
  • Oxford Centre for Diabetes, Endocrinology and Metabolism
    Oxford, OX37LJ, United Kingdom
09

References and documents

Publications

  • Labadzhyan A, Nachtigall LB, Fleseriu M, Gordon MB, Molitch M, Kennedy L, Samson SL, Greenman Y, Biermasz N, Bolanowski M, Haviv A, Ludlam W, Patou G, Strasburger CJ. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary. 2021 Dec;24(6):943-953. doi: 10.1007/s11102-021-01163-2. Epub 2021 Jun 25. Erratum In: Pituitary. 2021 Dec;24(6):954. doi: 10.1007/s11102-021-01177-w. PubMed 34173129 ↗
  • Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708. doi: 10.1210/jc.2014-4113. Epub 2015 Feb 9. Erratum In: J Clin Endocrinol Metab. 2016 Oct;101(10):3863. doi: 10.1210/jc.2016-4113. J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa637. doi: 10.1210/clinem/dgaa637. PubMed 25664604 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2011
First posted
Aug 9, 2011
Start
Mar 2012
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Dec 1, 2015
Last update
Aug 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01412424
Lead sponsor
Chiasma, Inc.
Responsible party
Sponsor
First posted
Aug 9, 2011
Start date
Mar 2012
Primary completion
May 2014
Completion
May 2014
Results posted
Dec 1, 2015
Last update
Aug 17, 2017

Study contacts

Shlomo Melmed, MD
study chair · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion